Akademik Veri Yönetim Sistemi
50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care, Praha, Çek Cumhuriyeti, 19 - 21 Ekim 2022, cilt.44, ss.1513
Assessment of vaccination pattern and intention to receive a boost dose of COVID vaccine among patients with chronic disease conditions
Background and Objective: The COVID-19 pandemic is a serious public health threat that is overwhelming many aspects of the people’s life including physical, social, emotional and behavioural wellbeing. Comorbidities are associated with worse health outcomes, more complex clinical management, increased health care cost and death secondary to COVID-19 infection. Vaccine hesitancy is a complex phenomenon and context specific, varying across time, place, and vaccines. Recognizing such perceptions could assist decision makers in setting policies dealing with any worrisome regarding a boost COVID-19 dose. The aim of this study was to assess the pattern of vaccination and intention to receive a boost dose (s) of COVID-19 vaccine among patients with chronic disease conditions in Istanbul, Turkey.
Method: This was a descriptive, cross-sectional study conducted among a convenient sample size via direct interviews with patients having chronic disease conditions attending the community pharmacies in Istanbul, Turkey, using a structured validated questionnaire consisting of 21-item to assess the pattern of vaccination and intention to receive a boost dose (s) of COVID-19 vaccine.
Main outcome measures: Frequency of vaccination patterns and intention to receive a boost dose (s) of COVID-19 vaccine.
Results: A total of 162 patients with an average age of 56 ± 15.0 years were included in this study. Majority of the respondents were females (54.3%), had university and secondary education level (35.2%, 29%, respectively), non-cigarette smokers (73.5%). 90.1% had more than one disease condition. Hypertension and Type 2 Diabetes Mellitus represented the major chronic disease conditions (44.4%, 26.5%, respectively) with a median duration of 12.2 ± 8.7 and 10.7 ± 7.4 years, respectively. 62.3% of the respondents had no history of COVID infection, 96.3% were fully vaccinated, and of whom 90.1% received full doses of Pfizer vaccination. 50.6% were not worried about the vaccine side effects and 67.3% (n = 109) did not report any side effects after vaccination. Out of those suffers, 75.5% (40/53) reported mild side effects after vaccination which lasted for 24 h, while the remaining 24.5% reported moderate side effects which required medical intervention. 94.4% of the participants reported provision of information to control symptoms of side effects after vaccination, of whom 87.7% were followed by their healthcare providers. 50.6% worried from being re-infected. 81.5% and 12.3% were provided full information about the importance of a boost vaccine dose based on physician and community pharmacist advice, respectively. 92% and 71.6% reported a strong intention to receive a boost vaccine dose from the same previous brand, respectively.
Conclusion: This study highlights the importance and benefits of COVID-19 vaccination demonstrated by a high rate of intention to receive a boost vaccine dose despite the incidence of side effects and dispositional worry which motivates vaccination behaviours during pandemic events when benefits of vaccination are high particularly among patients with chronic disease conditions.
Disclosure of Interest: None Declared.